抗CD22单克隆抗体Epratuzumab治疗非霍奇金淋巴瘤  

Epratuzumab as anti-CD22 monocione antibody in treatment of non-Hodgkin＇s iymphoma

作　　者：秦燕（综述）[1] 石远凯（审校）[1] 何小慧（审校）[1] 

机构地区：[1]中国协和医科大学中国医学科学院肿瘤医院肿瘤研究所内科,北京100021

出　　处：《国际肿瘤学杂志》2007年第3期229-231,共3页Journal of International Oncology

摘　　要：epratuzumab是抗CD22的人源化单克隆抗体。CD22分子仅在成熟B淋巴细胞表面表达，约85％的B细胞非霍奇金淋巴瘤表达CD22分子。Ⅰ和Ⅱ期临床研究显示，epratuzumab的毒副作用轻，耐受性良好，对于滤泡型和弥漫大B细胞型淋巴瘤有较好疗效，且可能与美罗华具有协同作用，很有希望成为治疗B细胞非霍奇金淋巴瘤的治疗药物。Epratuzumab is a humanized anti-CD22 monoclonal antibody. CD22 molecule only expresses on the surface of mature B lymphocytes and appoximately 85% of B cell non-Hodgkin＇ s lymphomas express CD22. Several phase Ⅰ and Ⅱ clinical trials indicate that epratuzumab is well tolerated with mild toxicity , has effective activity in both follicular and diffuse large B cell lymphoma and may has synergetic effects with rituximab,all these demonstrat that epratuzumab may become a promising anti-lymphoma agent.

关 键 词：非霍奇金淋巴瘤 抗体 单克隆 CD22 

分 类 号：R329.28[医药卫生—人体解剖和组织胚胎学] R730.5[医药卫生—基础医学]